Related Experiment Video

Updated: Jun 28, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

724

Reduced plasma cortistatin is related to clinical parameters in patients with essential hypertension

Wenjia Chen1, Yu Fu1, Yuanyuan Jin1

  • 1Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Peptides
|April 20, 2024
PubMed

Insights

Plasma Cortistatin (CST) levels are lower in hypertensive patients, suggesting CST may be a protective target for managing hypertension and improving blood pressure control.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Hypertension Studies

Background:

  • Cortistatin (CST) is an endogenous polypeptide with known cardiovascular protective effects.
  • The specific role of CST in the context of hypertension is not well-established.
  • Investigating CST levels in hypertensive individuals is crucial for understanding its potential involvement.

Purpose of the Study:

  • To determine plasma CST levels in patients with essential hypertension compared to normotensive individuals.
  • To explore the correlation between plasma CST levels and blood pressure.
  • To analyze the relationship between CST and metabolic parameters, and cardiac structure/function.

Main Methods:

  • A hospital-based study involving 81 essential hypertension patients and 75 normotensive subjects.
  • Measurement of plasma CST levels using enzyme-linked immunosorbent assay (ELISA).
  • Collection of data on blood pressure, metabolic indicators (TC, TGs, FGB, Scr), and cardiac parameters.

Main Results:

  • Plasma CST levels were significantly lower in hypertensive patients compared to controls.
  • Hypertensive patients with uncontrolled blood pressure exhibited lower CST levels than those with controlled blood pressure.
  • Plasma CST showed a significant negative correlation with systolic blood pressure (SBP) and serum creatinine (Scr).

Conclusions:

  • Reduced circulating CST concentrations are associated with hypertension.
  • Elevated CST levels were observed following blood pressure control in hypertensive patients.
  • CST emerges as a potential endogenous protective factor and therapeutic target for hypertension.
Abstract

Keywords:
Bioactive neuropeptideCardiovascular protective effectsCortistatinHypertension

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.4K
Femoral Arterial and Venous Catheterization for Blood Sampling, Drug Administration and Conscious Blood Pressure and Heart Rate Measurements09:38

Femoral Arterial and Venous Catheterization for Blood Sampling, Drug Administration and Conscious Blood Pressure and Heart Rate Measurements

Published on: January 24, 2012

124.8K

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
679
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422